Zimmer Biomet

NYSE: ZBH

Stock price

91.12 USD

(+Infinity%) NaN day

Financial Performance

Share

5Y price score: (53)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: (17.4)%

DATE RANGE:

US$ Per
Share

By default your notes are visible only to you.

79.1

52-week range

108.2

91.12

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

10.2 %

Dividend Yield TTM

1.1 %

Market cap $

$ 17,628

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

23.7

Price / Book TTM

1.4

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

(1.2)

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

(3) %

(35.6) %

(17.4) %

Free cash flow per share growth

32.2 %

40.4 %

106.2 %

Earnings per share growth

(19.9) %

629.9 %

1,265.4 %

Founded: 1,927

Employees: 17,000

Business Summary:Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.

Fair Value Reference Estimate

Latest Earnings Call Takeaways

Annual Reports, Presentations And IR Contacts

Go to the website

Zimmer Biomet — Financial Overview, Stock Price, Market Cap

Zimmer Biomet is a company. Founded in 1927. As of July 20, 2026, the company's market capitalization is $17628257440 with a current stock price of $91.12.